Dataset from A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).

本研究旨在评估沙利前列醇（xaliproden）减缓轻中度阿尔茨海默病患者认知功能与整体功能衰退的潜在能力。参与本研究的患者将每日口服一次沙利前列醇或安慰剂（无活性成分片剂）。